SCHEMBL12419653

SCHEMBL12419653

OB(O)c1ccc([C@H]2OC[C@H](c3ccccc3)CO2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C19 P33261 1/20 0.42
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
MGLL Q99685 1/20 0.41
TSHR P16473 2/20 0.38
KCNA4 P22459 1/20 0.33
KCNA1 Q09470 1/20 0.33
KCNAB1 Q14722 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC18A3 Q16572 2/20 0.33
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446097 0.81 ESR2 (0.46) MEN1KMT2ACYP2C19TSHR
SCHEMBL12419661 0.81 TSHR (0.44) ENPP2CA4CA6CA5ACA7
SCHEMBL12419657 0.81 TSHR (0.44) ENPP2CA4CA6CA5ACA7
SCHEMBL12419660 0.81 TSHR (0.44) ENPP2CA4CA6CA5ACA7
SCHEMBL12419654 0.81 TSHR (0.44) ENPP2CA4CA6CA5ACA7
SCHEMBL15863768 0.76 ENPP2 (0.41) ENPP2CA4CA6CA5ACA7
SCHEMBL27248261 0.76 ENPP2 (0.41) ENPP2CA4CA6CA5ACA7
SCHEMBL9892741 0.76 ENPP2 (0.41) ENPP2CA4CA6CA5ACA7
SCHEMBL12419658 0.76 NPC1 (0.34) MEN1KMT2ACYP2C19TSHRSLC18A3
SCHEMBL12419651 0.76 NPC1 (0.34) MEN1KMT2ACYP2C19TSHRSLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 ENPP2 68/4885CA4 887/4885CA6 987/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 ENPP2 68/4885CA4 887/4885CA6 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.